drugset / Trial / NCT02369796
A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effects on serum testosterone after 4 weeks of subcutaneous (SC) dose administration, with different doses and dosing frequencies of TAK-448 to overweight/obese males with hypogonadotropic hypogonadism.
Timeline
- Start
- 2015-02
- Primary completion
- 2015-10
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAK-448 | Small molecule | 0.1 ug | Subcutaneous |
| Subject | TAK-448 | Small molecule | 0.3 ug | Subcutaneous |
| Subject | TAK-448 | Small molecule | 1 ug | Subcutaneous |
| Subject | TAK-448 | Small molecule | 3 ug | Subcutaneous |